Business
Replacement - NIH Licensing Agreeme
Replacement - NIH Licensing Agreeme.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nThis announcement replaces the announcement made on 11 May 2010 and contains\nchanges to the definitions of the relevant parties.\n\n Scancell Holdings Plc \n\n (`Scancell') \n\n National Institutes of Health Licensing Agreement \n\nScancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer\nvaccines, is pleased to announce it has signed a worldwide non-exclusive\nlicensing agreement with the National Institutes of Health (`NIH'), an agency\nof the United States Department of Health and Human Services, for use of the\nmelanoma antigens TRP-2 and gp100, developed in the laboratory of Steven A.\nRosenberg, M.D., Ph.D., at the National Cancer Institute. These antigens will\nbe utilized as key components of Scancell's lead ImmunoBody® vaccine for\nmelanoma, SCIB1.\n\nUnder the agreement, Scancell has agreed to pay the US Public Health Service an\nundisclosed upfront fee in addition to certain milestone fees and a royalty on\nfuture sales of SCIB1. Scancell will have the right to develop and\ncommercialise its ImmunoBody® vaccines for the treatment of melanoma in humans\nincorporating epitopes from these targets.\n\nImmunoBody® vaccines generate the high-avidity T-cells that kill cancer cells,\nwhich may overcome the current limitations of most cancer vaccines. Scancell is\nexpected to commence its Phase I clinical trials for SCIB1 in Q2 2010.\n\nDavid Evans, chairman of Scancell, commented:\n\n\"This agreement strengthens Scancell's IP position around SCIB1 and enables the\nCompany to move forward towards its proposed clinical trials of the melanoma\nvaccine.\"\n\n -ENDS- \n\nFor Further Information:\n\nDavid Evans, Chairman Scancell Holdings Plc + 44 774 008 4452 \n \nProfessor Lindy Durrant, CEO Scancell Holdings Plc + 44 207 245 1100 \n \nKirsty Corcoran/John Bick Hansard Communications + 44 207 245 1100 \n \nRoss Andrews / Tom Rowley Zeus Capital + 44 161 831 1512 \n\nAbout Scancell\n\nScancell is developing novel therapeutic vaccines for the treatment of cancer\nand infectious diseases based on its groundbreaking ImmunoBody® technology\nplatform. Scancell's first cancer vaccine SCIB1 is being developed for the\ntreatment of melanoma and is expected to enter clinical trials in 2010.\n\nTreating cancer by vaccination allows small non-toxic doses of a vaccine to be\nadministered to a patient, stimulating an i...